The Infectious Diseases Data Observatory (IDDO) will be hosting a webinar on the radical cure of P. vivax malaria and what we can do better on 3 February 2022 at 12pm GMT. Find out more and sign up here to join our one-hour research webinar with presentations and an expert discussion.
Two new studies using WWARN-hosted clinical trial data show that the dosing of the 8-aminoquinoline drugs primaquine and tafenoquine can be substantially improved. These analyses include the majority of all studied P. vivax malaria patients who received 8-aminoquinoline drugs over the last 20 years. Laboratory work confirms these findings and provides important new information on the mechanism of action of these essential medicines.
· Dr Rob Commons, Menzies School of Health Research, on 8AQ efficacy in clinical trials
· Dr Alison Roth, Walter Reed Army Institute of Research, on laboratory studies assessing hypnozoitocidal activity
· Dr James Watson, Oxford University Clinical Research Unit, on the reassessment of tafenoquine pharmacometrics
· Discussion chaired by Dr Chau Nguyen Hoang, Oxford University Clinical Research Unit, and Professor Sir Nicholas White, Mahidol Oxford Research Unit